| Hans-Günter Meyer-Thompson | Naloxon
EMCDDA. Take-home naloxone programmes in Europe
EMCDDA. Take-home naloxone programmes in Europe
Overview
Naloxone is used worldwide in medical emergencies to reverse respiratory depression caused by opioid overdose. It has no effect on non-opioid drug overdoses, no dependency potential and a high safety margin. Discovered and patented at the beginning of the 1960s, the US Food and Drug Administration (FDA) approved the first naloxone solution for intravenous, intramuscular and subcutaneous injection in 1971.
This publication describes the current state of take-home naloxone programmes throughout Europe, including the range of products used, the scale of implementation and price. (EMCDDA, Lissabon, 2023)
https://www.emcdda.europa.eu/publications/topic-overviews/take-home-naloxone_en